Public Profile

Argenx

Argenx SE, a leading biotechnology company headquartered in the Netherlands, is at the forefront of developing innovative therapies for severe autoimmune diseases and cancer. Founded in 2008, Argenx has made significant strides in the industry, particularly with its proprietary antibody engineering platform, which enables the creation of unique therapeutic candidates. The company’s flagship product, efgartigimod, has garnered attention for its potential to transform treatment paradigms in conditions like myasthenia gravis. With a strong presence in Europe and North America, Argenx has established itself as a key player in the biopharmaceutical sector, recognised for its commitment to advancing patient care through cutting-edge science and strategic partnerships.

DitchCarbon Score

How does Argenx's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

50

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

25

Industry Benchmark

Argenx's score of 50 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.

97%

Let us know if this data was useful to you

Argenx's reported carbon emissions

In 2024, Argenx reported total carbon emissions of approximately 231,769,000 kg CO2e. This figure includes 3,788,000 kg CO2e from Scope 1 emissions, 534,000 kg CO2e from Scope 2 emissions (market-based), and a significant 227,447,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 183,781,000 kg CO2e. In comparison, the 2023 emissions data showed a total of approximately 433,353,000 kg CO2e, with Scope 1 emissions at 378,000 kg CO2e, Scope 2 emissions at 189,000 kg CO2e (market-based), and Scope 3 emissions reaching about 432,786,000 kg CO2e. This indicates a notable reduction in total emissions from 2023 to 2024. Argenx has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by the middle of this decade (2025). These targets reflect the company's commitment to achieving significant reductions in its direct and indirect emissions, aligning with industry standards for climate action.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20232024
Scope 1
378,000
0,000,000
Scope 2
189,000
000,000
Scope 3
432,786,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Argenx's primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Argenx is in NL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Argenx is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Molecular Partners AG

CH
Health and social work services (85)
Updated 3 days ago

Hikma Pharmaceuticals

GB
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Basilea Pharmaceutica

CH
Health and social work services (85)
Updated 4 days ago

STADA Arzneimittel Aktiengesellschaft

DE
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

Indivior

US
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

NIOX Group Plc

GB
Health and social work services (85)
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers